Medpace Holdings, Inc. $MEDP is Riverbridge Partners LLC’s 5th Largest Position

Riverbridge Partners LLC reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 365,088 shares of the company’s stock after selling 68,936 shares during the period. Medpace makes up about 3.2% of Riverbridge Partners LLC’s investment portfolio, making the stock its 5th biggest position. Riverbridge Partners LLC’s holdings in Medpace were worth $187,714,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of MEDP. Kaufman Rossin Wealth LLC bought a new position in Medpace in the 3rd quarter worth $395,000. Northwest Wealth Management LLC purchased a new position in shares of Medpace in the third quarter worth $211,000. Brighton Jones LLC grew its stake in Medpace by 160.4% during the third quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after acquiring an additional 2,501 shares in the last quarter. Trust Point Inc. increased its holdings in shares of Medpace by 13.9% in the third quarter. Trust Point Inc. now owns 2,211 shares of the company’s stock worth $1,137,000 after purchasing an additional 270 shares during the last quarter. Finally, Congress Asset Management Co. increased its stake in Medpace by 12.5% in the 3rd quarter. Congress Asset Management Co. now owns 64,695 shares of the company’s stock worth $33,264,000 after acquiring an additional 7,190 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on MEDP shares. Truist Financial set a $555.00 target price on shares of Medpace in a report on Monday, October 27th. Robert W. Baird set a $613.00 price target on Medpace in a research report on Friday, October 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday. Jefferies Financial Group increased their price target on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a report on Tuesday, September 9th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and a consensus target price of $490.82.

Medpace Stock Performance

Medpace stock opened at $568.36 on Monday. The company has a market capitalization of $16.01 billion, a PE ratio of 39.75, a P/E/G ratio of 2.14 and a beta of 1.43. The company has a 50 day moving average price of $574.72 and a 200-day moving average price of $473.10. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $626.26.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same quarter in the prior year, the company earned $3.01 EPS. The business’s revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, President Jesse J. Geiger sold 21,503 shares of Medpace stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total value of $12,808,476.98. Following the transaction, the president owned 15,000 shares of the company’s stock, valued at $8,934,900. The trade was a 58.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This trade represents a 42.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 387,925 shares of company stock worth $233,386,647. 20.30% of the stock is owned by corporate insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.